Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial

The Lancet Respiratory Medicine

Volumn 4, Issue 9, 2016, Pages 720-730

  Jordan, Rachel E ^a   Adab, Peymané ^a   Sitch, Alice ^a   Enocson, Alexandra ^a   Blissett, Deirdre ^a   Jowett, Sue ^a   Marsh, Jen ^a   Riley, Richard D ^b   Miller, Martin R ^a   Cooper, Brendan G ^c   Turner, Alice M ^d   Jolly, Kate ^a   Ayres, Jon G ^a   Haroon, Shamil ^a   Stockley, Robert ^c   Greenfield, Sheila ^a   Siebert, Stanley ^a   Daley, Amanda J ^a   Cheng, K K ^a   Fitzmaurice, David ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CASE FINDING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; SMOKING; SPIROMETRY; CLUSTER ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; MASS SCREENING; MIDDLE AGED; PATIENT REFERRAL; POISSON DISTRIBUTION; PRIMARY HEALTH CARE; PROCEDURES; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SYMPTOM ASSESSMENT; UNITED KINGDOM; VITAL CAPACITY;

ADULT; AGED; CLUSTER ANALYSIS; COST-BENEFIT ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; POISSON DISTRIBUTION; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERRAL AND CONSULTATION; REGRESSION ANALYSIS; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; SYMPTOM ASSESSMENT; UNITED KINGDOM; VITAL CAPACITY;

EID: 84978786048     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30149-7     Document Type: Article

References (34)

1. 1 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. http://goldcopd.org/gold-reports/, 2015 (accessed May 30, 2016).
2. 2 European Respiratory Society. European lung white book. Respiratory health and disease in Europe. 2015. Chapter 2 The economic burden of lung diseases. http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease (accessed May 30, 2016).
3. 3 Halbert, RJ, Natoli, JL, Gano, A, Badamgarav, E, Buist, AS, Mannino, DM, Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28 (2006), 523–532.
4. 4 Jordan, R, Lam, K-B, Cheng, K, et al. Case finding for chronic obstructive pulmonary disease: a model for optimizing a targeted approach. Thorax 65 (2010), 492–498.
5. 5 Mannino, DM, Gagnon, RC, Petty, TL, Lydick, E, Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 160 (2000), 1683–1689.
6. 6 Buist, AS, McBurnie, M, Vollmer, WM, et al., on behalf of the BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370 (2007), 741–750.
7. 7 British Lung Foundation. Invisible lives. Chronic obstructive pulmonary disease (COPD)–finding the missing millions. http://spirohub.com/wp-content/uploads/2016/01/BLF-Invisible-Lives-report.pdf, 2007 (accessed July 4, 2016).
8. 8 Department of Health. An outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma in England. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_127974, 2011 (accessed May 30, 2016).
9. 9 COPD Foundation. Am I at risk for COPD?. http://www.copdfoundation.org/Take-Action/Get-Tested/Am-I-At-Risk.aspx (accessed July 4, 2016).
10. 10 Haroon, SM, Jordan, RE, O'Beirne-Elliman, J, Adab, P, Effectiveness of case-finding strategies for COPD in primary care: a systematic review and meta-analysis. NPJ Prim Care Respir Med, 25, 2015, 15056.
11. 11 Yawn, BP, Duvall, K, Peabody, J, The impact of screening tools on diagnosis of chronic obstructive pulmonary disease in primary care. Am J Prev Med 47 (2014), 563–575.
12. 12 Jordan, RE, Adab, P, Jowett, S, et al. TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versus routine practice in primary care: protocol. BMC Pulm Med, 14, 2014, 157.
13. 13 Health and Social Care Information Centre (HSCIC). Quality and outcomes framework. http://www.hscic.gov.uk/qof (accessed May 30, 2016).
14. 14 Carter, B, Hood, K, Balance algorithm for cluster randomised trials. BMC Med Res Methodol, 8, 2008, 65.
15. 15 National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. NICE clinical guideline 101. https://www.nice.org.uk/guidance/cg101, 2010 (accessed May 30, 2016).
16. 16 Miller, MR, Hankinson, J, Brusasco, V, et al. ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J 26 (2005), 319–338.
17. 17 Hankinson, JL, Eschenbacher, B, Townsend, M, Stocks, J, Quanjer, PH, Use of forced vital capacity and forced expiratory volume in 1 second quality criteria for determining a valid test. Eur Respir J 45 (2015), 1283–1292.
18. 18 Quanjer, PH, Stanojevic, S, Cole, TJ, et al. ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 40 (2012), 1324–1343.
19. 19 Zou, G, A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159 (2004), 702–706.
20. 20 National Institute for Health Research. Primary Care Resource template. http://www.crn.nihr.ac.uk/resources/resource-template/, June 5, 2014 (accessed Aug 11, 2015).
21. 21 Haroon, S, Adab, P, Griffin, C, Jordan, R, Case finding for chronic obstructive pulmonary disease in primary care: a pilot randomised controlled trial. Br J Gen Pract 63 (2013), 26–27.
22. 22 Dirven, JA, Tange, HJ, Muris, JW, van Haaren, KM, Vink, G, van Schayck, OC, Early detection of COPD in general practice: patient or practice managed? A randomised controlled trial of two strategies in different socioeconomic environments. Prim Care Respir J 22 (2013), 331–337.
23. 23 van den Boom, G, van Schayck, CP, van Möllen, MP, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Am J Respir Crit Care Med 158 (1998), 1730–1738.
24. 24 van den Boom, G, Rutten-van Molken, MP, Folgering, H, van Weel, C, van Schayck, CP, The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program. Prev Med 30 (2000), 302–308.
25. 25 Raluy-Callado, M, Lambrelli, D, MacLachlan, S, Khalid, JM, Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013. Int J Chron Obstruct Pulmon Dis 10 (2015), 925–937.
26. 26 Sestini, P, Renzoni, E, Robinson, S, Poole, P, Ram, FSF, Short-acting beta2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 4, 2002 CD001495.
27. 27 Kew, KM, Dias, S, Cates, CJ, Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev, 3, 2014 CD010844.
28. 28 Zwerink, M, Brusse-Keizer, M, van der Valk, PD, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3, 2014 CD002990.
29. 29 Godtfredsen, NS, Lam, TH, Hansel, TT, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 32 (2008), 844–853.
30. 30 Poole, PJ, Chacko, E, Wood-Baker, R, Cates, CJ, Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 1, 2006 CD002733.
31. 31 Puhan, MA, Gimeno-Santos, E, Scharplatz, M, Troosters, T, Walters, EH, Steurer, J, Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 10, 2011 CD005305.
32. 32 Guirguis-Blake, JM, Senger, CA, Webber, EM, Mularski, RA, Whitlock, EP, Screening for chronic obstructive pulmonary disease. Evidence report and systematic review for the US Preventive Services Task Force. JAMA 315 (2016), 1378–1393.
33. 33 Swanney, MP, Ruppel, G, Enright, PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 12 (2008), 1046–1051.
34. 34 Haroon, S, Adab, P, Riley, RD, Marshall, T, Lancashire, R, Jordan, RE, Predicting risk of COPD in primary care: development and validation of a clinical risk score. BMJ Open Respir Res, 2, 2015, e000060.